Clinical Trials
9 trialsNCT00470301 2021-02-16
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00082810 2018-11-01
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00070252 2015-05-04
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00100750 2015-01-13
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00052728 2013-06-19
Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00049114 2013-06-06
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077363 2013-02-27
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005842 2013-02-11
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00050141 2013-02-01
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed